Preview

Ингибиторы ДПП-4 и гипогликемии у больных сахарным диабетом 2-го типа

https://doi.org/10.14341/probl201359572-80

Полный текст:

Аннотация

Количество гипогликемий остается достаточно высоким в популяции больных сахарным диабетом 2-го типа (СД2), особенно у получающих традиционную сахароснижающую терапию. Гипогликемия является одним из наиболее частых нежелательных явлений, с которыми сталкивается врач при лечении СД2. Вместе с тем появляются новые возможности в терапии СД2, позволяющие избежать развития этого состояния.

Об авторе

Iu Khalimov



Список литературы

1. Desouza C.V., Bolli G.B., Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. Diabet Care 2010; 33: 1389-1394.

2. Cryer P.E. Severe hypoglycemia predicts mortality in diabetes. Diabet Care 2012; 35: 1814-1816.

3. Zoungas S., Patel A., Chalmers J., de Galan B.E., Li Q., Billot L., Woodward M., Ninomiya T., Neal B., MacMahon S., Grobbee D.E., Kengne A.P., Marre M. Heller Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010; 363: 1410-1418.

4. Holstein A., Patzer O.M., Machalke K., Holstein J.D., Stumvoll M., Kovacs P. Substantial increase in incidence of severe hypoglycemia between 1997-2000 and 2007-2010. A German longitudinal population-based study. Diabet Care 2012; 35: 5: 972-975.

5. Bremer J.P., Jauch-Chara K., Hallschmid M., Schmid S., Schultes B. Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes Diabet Care 2009; 32: 1513-1517.

6. Brierley E.J., Broughton D.L., James O.F., Alberti K.G. Reduced awareness of hypoglycaemia in the elderly despite an intact counter-regulatory response. QJM 1995; 88: 439-445.

7. Дедов И.И., Шестакова М.В., Александров А.А. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой. М 2011.

8. Alvarez Guisasola F., Tofé Povedano S., Krishnarajah G., Lyu R., Mavros P., Yin D. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAPDM) Study. Diabet Obes Metabol 2008; 10: Suppl 1: 25-32.

9. Vexiau P., Mavros P., Krishnarajah G., Lyu R., Yin D. Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France. Diabet Obes Metabol 2008; 10: Suppl 1: 16-24.

10. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.

11. Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M., Marre M., Cooper M., Glasziou P., Grobbee D., Hamet P., Harrap S., Heller S., Liu L., Mancia G., Mogensen C.E., Pan C., Poulter N., Rodgers A., Williams B., Bompoint S., de Galan B.E., Joshi R., Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. ADVANCE Collaborative Group. N Engl J Med 2008; 358: 2560-2572.

12. Duckworth W., Abraira C., Moritz T., Reda D., Emanuele N., Reaven P.D., Zieve F.J., Marks J., Davis S.N., Hayward R., Warren S.R., Goldman S., McCarren M., Vitek M.E., Henderson W.G., Huang G.D. Glucose control and vascular complications in veterans with Type 2 Diabetes. N Engl J Med 2009; 360: 129-139.

13. Akram K., Pedersen-Bjergaard U., Carstensen B., Borch-Johnsen K., Thorsteinsson B. Frequency and risk factors of severe hypoglycaemia in insulin-treated type 2 diabetes: a cross-sectional survey. Diabet Med 2006; 23: 7: 750-756.

14. Quilliam B.J., Simeone J.C., Ozbay A.B. Risk factors for hypoglycemia-related hospitalization in patients with type 2 diabetes: a nested case-control study. Clin Ther 2011; 33: 11: 1781-1791.

15. Bloomfield H.E., Greer N., Newman D. Predictors and consequences of severe hypoglycemia in adults with diabetes: a systematic review of the evidence 2012; http://www.hsrd.research.va.gov/publications/esp/hypoglycemia-2012.pdf

16. Shorr R.I., Ray W.A., Daugherty J.R. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med 1997; 157: 1681-1686.

17. Davis T.M.E., Brown S.G.A., Jacobs I.G. Determinants of severe hypoglycemia complicating type 2 diabetes: the Fremantle diabetes study. J Clin Endocrinol Metabol 2010; 95: 5: 2240-2247.

18. Bruce D.G., Davis W.A., Casey G.P., Clarnette R.M., Brown S.G., Jacobs I.G., Almeida O.P., Davis T.M. Severe hypoglycaemia and cognitive impairment in older patients with diabetes: the Fremantle Diabetes Study. Diabetologia 2009; 52: 9: 1808-1815.

19. Davis S.N., Mann S., Briscoe V.J. Effects of intensive therapy and antecedent hypoglycemia on counterregulatory responses to hypoglycemia in type 2 diabetes. Diabetes 2009; 58: 701-709.

20. Miller M.E., Bonds D.E., Gerstein H.C. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ 2010; 340-344.

21. Inzucchi S.E., Bergenstal R.M., Buse J.B. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. Diabet Care 2012; 35: 1364-1379.

22. Deacon C.F. Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidylpeptidase-4 inhibitors. Diabet Obes Metabol 2007; 9: Suppl 1: 23-31.

23. Dejager S., Schweizer A. Minimizing the risk of hypoglycemia with vildagliptin: clinical experience, mechanistic basis, and importance in type 2 diabetes management. Diabet Ther 2011; 2: 2: 51-66.

24. Ahren B., Schweizer A., Dejager S. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metabol 2009; 94: 1236-1243.

25. Дедов И.И., Шестакова М.В. Инкретины: новая веха в лечении сахарного диабета 2-го типа. Практическое руководство для врачей. М: Дипак 2010.

26. Dejager S., Schweizer A., Foley J.E. Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus. Vascular Health Risk Management 2012; 8: 339-348.

27. Aroda V.R., Henry R.R., Han J. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther 2012; 34: 6: 1247-1258.

28. Schweizer A., Dejager S., Foley J.E. Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥=75 years: a pooled analysis from a database of clinical trials. Diabet Obes Metabol 2011; 13: 55-64.

29. Moen M.F., Zhan M., Hsu V.D. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 1121-1127.

30. Kothny W., Shao Q., Groop P.H., Lukashevich V. One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment. Diabet Obes Metabol 2012; 14: 11: 1032-1039.

31. Scherbaum W.A., Schweizer A., Mari A. Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycaemia. Diabet Obes Metabol 2008; 10: 675-682.

32. Matthews D.R., Dejager S., Ahren B. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabet Obes Metabol 2010; 12: 780-789.

33. Schweizer A., Dejager S., Foley J.E. Impact of insulin resistance, body mass index, disease duration, and duration of metformin use on the efficacy of vildagliptin. Diabet Ther 2012; 3: 1: 8 doi: 10.1007/s13300-012-0008-5.

34. Devendra D., Gohel B., Bravis V. Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan. Int J Clin Pract 2009; 63: 1446-1450.

35. Bader G., Geransar P., Schweizer A. Vildagliptin more effectively achieves a composite endpoint of HbA1c<7.0% without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment. Diabet Res Clin Pract 2013; Mar 25. doi:pii: S0168-8227(13)00089-2. 10.1016/j.diabres.2013.03.011

36. Blüher M., Kurz I., Dannenmaier S., Dworak M. Efficacy and safety of vildagliptin in clinical practice-results of the PROVIL-study. World J Diabet 2012; 15: 3: 9: 161-169.

37. Mathieu C., Bader G., Hagner N. Effectiveness and safety of vildagliptin compared with other oral antidiabetic drugs in patients with type 2 diabetes: results from a large worldwide cohort study (EDGE). Poster 863 presented at EASD 2012.

38. Fonseca V., Schweizer A., Albrecht D. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007; 50: 1148-1155.

39. Kothny W., Foley J., Kozlovski P., Shao Q., Gallwitz B., Lukashevich V. Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus. Diabet Obes Metabol 2013; 15: 3: 252-257.


Для цитирования:


. Ингибиторы ДПП-4 и гипогликемии у больных сахарным диабетом 2-го типа. Проблемы Эндокринологии. 2013;59(5):72-80. https://doi.org/10.14341/probl201359572-80

For citation:


Khalimov I.S. DPP-4 inhibitors and hypoglycemia in the patients with type 2 diabetes mellitus. Problems of Endocrinology. 2013;59(5):72-80. (In Russ.) https://doi.org/10.14341/probl201359572-80

Просмотров: 31


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 0375-9660 (Print)
ISSN 2308-1430 (Online)